June 5, 2025
3:00 pm – 5:00 pm
MasterSwitch Bio is an mRNA company that treats end stage liver disease (ESLD) with cirrhosis from MASH/metALD/ALD. Their labs are based at the University of Pennsylvania and the University of Pittsburgh. Dr. Drew Weissman (Nobel for Medicine 2023) is our mRNA developer and co-founder.
Their science team has established a complete reversal of disease and cirrhosis in three ESLD cirrhotic models: rat, human hepatocyte and whole explanted human livers.
MasterSwitch Bio’s technology is a modified mRNA of HNF4α (hepatocyte nuclear factor-4 alpha) the master transcription regulator for hepatocyte core function. Upregulating HNF4α increases and normalizes downstream core function proteins that play a central role in the hepatocyte’s health from lipid metabolism to albumin and coagulation. Restoring core function also resolves portal hypertension, inflammation, ascites, encephalopathy and cirrhosis and restores native expression of HNF4α, indicating a sustained correction of the cell’s transcriptional network.
OCMS Bio, LLC
Conventional discovery processes yield passable, sub-optimal antibody drugs. OCMS proprietary high throughput function first analysis cuts years from development time and millions from cost while creating the best possible next generation antibodies. OCMS first asset, an anti-RSV antibody, has reached the preclinical stage; the second, a muscle mass enhancer, is close behind; both have demonstrated materially superior clinically differentiated competitive profiles.”
Recombination Therapeutics is a precision oncology company on a mission to overcome drug resistance in genetically defined cancers. We target the DNA repair pathways that tumors hijack to survive and adapt —restoring sensitivity to standard treatments and extending the durability of response. Our lead program, RTx-303, is a potentially best-in-class, oral Polθ inhibitor that eradicates BRCA-mutant tumors in preclinical models and overcomes resistance to PARP inhibitors, radiation and chemotherapy.